Have any questions? 706-721-6582 or cts@augusta.edu
- A PHASE 1/2A, MULTICENTER, OPEN-LABEL STUDY OF LYC-55716 IN ADULT SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC CANCER
Clinical Trial
A PHASE 1/2A, MULTICENTER, OPEN-LABEL STUDY OF LYC-55716 IN ADULT SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC CANCER
The purpose of this research study is to measure how well and how safe LYC-55716 (study drug) is in treating patients with locally advanced or metastatic cancer. This is the first in human study for LYC-55716, however animal studies have shown that LYC-55716 may be usful as treatment for locally advanced or metastatic cancer. There will be two phases to this study; Phase 1 portion was conducted first, followed by the phase 2a portion.The Phase 1 portion examind the safety of different doses of LYC-55716 to determne the appropriate dose to be used for patients in the Phase 2a portion. The Phase 2a portion of the study will examine the body's response to the study drug.
Eligibility Criteria
- Subject may be male or female at least 18 years of age. Subject must have at least 1 measureable lesion. Please see the protocol for the entire list of eligibility criteria.